Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer
Cells · 27.02.2023 · 12 (5) · 754
DOI: 10.3390/cells12050754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 27.02.2023. Verfasst von Diane Frankel und 8 weiteren Autor:innen. Beteiligte Einrichtung: Aix Marseille University, APHM, INSERM, MMG, la Timone Hospital, Cell Biology Laboratory, 13005 Marseille, France. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Adenocarcinoma of Lung. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Lung cancer has become the leading cause of cancer death for men and women. Most patients are diagnosed at an advanced stage when surgery is no longer a therapeutic option. At this stage, cytological samples are often the less invasive source for diagnosis and the determination of predictive markers. We assessed the ability of cytological samples to perform diagnosis, and to establish molecular profile and PD-L1 expression, which are essential for the therapeutic management of patients.
Methods
We included 259 cytological samples with suspected tumor cells and assessed the ability to confirm the type of malignancy by immunocytochemistry. We summarized results of molecular testing by next generation sequencing (NGS) and PD-L1 expression from these samples. Finally, we analyzed the impact of these results in the patient management.
Results
Among the 259 cytological samples, 189 concerned lung cancers. Of these, immunocytochemistry confirmed the diagnosis in 95%. Molecular testing by NGS was obtained in 93% of lung adenocarcinomas and non-small cell lung cancer. PD-L1 results were obtained in 75% of patients tested. The results obtained with cytological samples led to a therapeutic decision in 87% of patients.
Conclusion
Cytological samples are obtained by minimally invasive procedures and can provide enough material for the diagnosis and therapeutic management in lung cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aix Marseille University, APHM, INSERM, MMG, la Timone Hospital, Cell Biology Laboratory, 13005 Marseille, France.
- Aix Marseille University, APHM, CHU Nord, Oncobiology Laboratory, 13015 Marseille, France.
- Aix Marseille University, CNRS, INP, Inst Neurophysiopathol, 13005 Marseille, France.
- Multidisciplinary Oncology and Therapeutic Innovations, Marseille University Hospital, APHM, 13015 Marseille, France.
- Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, APHM, 13015 Marseille, France.
- Aix Marseille University, APHM, Anatomopathology Department, 13005 Marseille, France.
ORCID-Profile: Diane Frankel, Laurent Greillier, Philippe Astoul, Elise Kaspi, Patrice Roll
Zitieren
APA
Frankel, D., Nanni, I., Ouafik, L., Greillier, L., Dutau, H., Astoul, P., Daniel, L., Kaspi, E., & Roll, P. (2023). Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer. Cells, 12(5), 754. https://doi.org/10.3390/cells12050754
Vancouver
Frankel D, Nanni I, Ouafik L, Greillier L, Dutau H, Astoul P, et al. Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer. Cells. 2023;12(5):754. doi:10.3390/cells12050754
BibTeX
@article{Frankel2023,
author = {Frankel, Diane and Nanni, Isabelle and Ouafik, L'Houcine and Greillier, Laurent and Dutau, Hervé and Astoul, Philippe and Daniel, Laurent and Kaspi, Elise and Roll, Patrice},
title = {Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer},
journal = {Cells},
year = {2023},
volume = {12},
number = {5},
pages = {754},
doi = {10.3390/cells12050754}
}
EUVIMED